Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus

Abstract

Objective

The objective of this report is to analyse retinal changes over a five-year period, assessed by spectral domain-optical coherence tomography (SD-OCT), in patients from the Lupus-Cruces cohort treated with hydroxychloroquine (HCQ).

Methods

SD-OCT screening was performed annually between 2012 and 2017. Average macular thickness (AMT), ganglion cell layer thickness (GCLT) and qualitative data of retinal pigment epithelium (RPE) and external retina (ExtR) were collected prospectively. We compared data from 2012 (first) and 2017 (second) SD-OCT.

Results

We studied 110 patients and 195 eyes. No cases of HCQ toxicity were detected. At the time of the second SD-OCT, 99% patients had taken a daily dose of HCQ ≤5 mg/kg/day. The median time on HCQ was 133 months. The mean AMT and GCLT were significantly lower in both eyes at the second SD-OCT; however, all the differences were clinically insignificant at less than 1%. Qualitative analysis of RPE and ExtR showed no significant changes. Similar results were found among patients with risk factors for retinopathy. The comparison of patients with and without risk factors showed no differences.

Conclusions

This study shows clinically irrelevant retinal changes in an SLE cohort on HCQ treatment over a five-year follow-up. Our findings support the safety of long-term HCQ at doses ≤5 mg/kg/day.

Keywords

Antimalarials damage hydroxychloroquine retinopathy spectral-domain optical coherence tomography systemic lupus erythematosus toxicity

Get full access to this article

View all access options for this article.

References

Gordon

Amissah-Arthur

M-B

Gayed

et al.

The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 2018; 57: e1–e45.

Ruiz-Irastorza

Khamashta

. Hydroxychloroquine: The cornerstone of lupus therapy. Lupus 2008; 17: 271–273.

Ruiz-Irastorza

Ramos-Casals

Brito-Zeron

Khamashta

. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 2010; 69: 20–28.

Danza

Ruiz-Irastorza

. Infection risk in systemic lupus erythematosus patients: Susceptibility factors and preventive strategies. Lupus 2013; 22: 1286–1294.

Latasiewicz

Gourier

Yusuf

Luqmani

Sharma

Downes

. Hydroxychloroquine retinopathy: An emerging problem. Eye (Lond) 2017; 31: 972–976.

Melles

Marmor

. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132: 1453–1460.

Marmor

Kellner

Lai

Melles

Mieler

WF;

. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016; 123: 1386–1394.

de Sisternes

Rubin

Marmor

. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: Inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci 2015; 56: 3415–3426.

Ledingham

Gullick

Irving

et al.

BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2017; 56: 865–868.

10.

Marmor

. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 2012; 130: 461–469.

11.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

12.

Petri

Orbai

Alarcón

et al.

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

13.

Wolfe

Marmor

. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 775–784.

14.

Mackenzie

. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983; 75: 40–45.

15.

Hughes

. Hydroxychloroquine: An update. Lupus 2018; 27: 1402–1403.

16.

Ruiz-Irastorza

Egurbide

Pijoan

et al.

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577–583.

17.

Ruiz-Arruza

Lozano

Cabezas-Rodriguez

et al.

Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: An observational study. Arthritis Care Res (Hoboken) 2018; 70: 582–591.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB